Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a two-pronged approach to tackle major neurological disorders, focusing on multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company's pipeline aims to address conditions that affect hundreds of millions of people worldwide, where existing treatments often fall short.
Multiple sclerosis, a debilitating disease affecting an estimated 2.9 million people globally, is the target of Quantum BioPharma's Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. The company is supporting Lucid-MS's phase 2 development through an ongoing imaging collaboration with Massachusetts General Hospital, a key step in validating the drug's mechanism.
In addition to its MS focus, Quantum BioPharma has developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This product targets a widespread issue, as alcohol misuse contributes to numerous health and social problems.
The company's pipeline addresses two significant areas of unmet neurological need. For MS, current treatments often focus on managing symptoms or slowing progression, but Lucid-MS aims to offer a novel mechanism that could potentially repair damage caused by the disease. Meanwhile, unbuzzd provides a consumer-focused solution for the immediate cognitive and physiological effects of alcohol.
Investors can find the latest news and updates relating to QNTM in the company's newsroom at https://ibn.fm/QNTM.
